Aflatoxin B1:UserContributedInformation

From ToxBankWiki

Aflatoxin B1:UserContributedInformation
Jump to: navigation, search

Standard to Meet Compound Assessment
Criteria Notes
The in vivo therapeutic window is used to estimate an appropriate concentration for in vitro toxicity assays. This in vitro concentration should also be consistent with the exposure implied by pharmacokinetics parameters.
We prefer compounds that require metabolic activation, although standards that are active in themselves will be accepted if they have otherwise valuable properties. We require knowing the active metabolite, and we prefer compounds where the metabolite is stable and can be independently tested in order to verify the mechanism of toxicity as well as of metabolic activation in the test cell line.
Literature data for at least one, but not necessarily all, of the ‘omics datasets is desired. This requirement can be waived in special cases.
The IC50’s for in vitro efficacy and toxicity should be consistent with the therapeutic ratio observed in the clinic. These parameters will be dependent on specific cell type and culture conditions, but differences of more than 30-fold in the in vitro vs. in vivo therapeutic ratios should be considered suspect and carefully justified.
This is not a requirement, but compounds utilized in the EPA testing program can be assumed to have physical properties verified to be suitable for in vitro cellular assays.
Sparing soluble compounds may be assayed for solubility in serum and the percent serum used specified here.
This property will be measured when a sample of compound becomes available.

Authors of this ToxBank wiki page

David Bower, Egon Willighagen
Personal tools
Renal Toxins
Special Substances
Undifferentiated Stem Cells
hiPSC Lines
Liver Cell Lines
iPS-derived Cardiomyocytes
Reagents (Growth Factors)
Reagents (Antibodies)
Reagents (Others)
Suppliers (Cells)